Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antiviral drug |
| gptkbp:ATCCode |
none (not assigned)
|
| gptkbp:CASNumber |
1173755-55-4
|
| gptkbp:chemicalFormula |
C15H20N4O6S
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:developedBy |
gptkb:Astex_Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
guadecitabine
|
| gptkbp:intendedUse |
treatment of acute myeloid leukemia
treatment of myelodysplastic syndromes |
| gptkbp:IUPACName |
[(2R,4S,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] (2R,4S,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolane-3-carbothioate
|
| gptkbp:mechanismOfAction |
DNA methyltransferase inhibitor
|
| gptkbp:molecularWeight |
400.41 g/mol
|
| gptkbp:relatedTo |
gptkb:azacitidine
gptkb:decitabine |
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:status |
investigational drug
|
| gptkbp:synonym |
gptkb:SGI-110
5-aza-2'-deoxycytidine dinucleotide |
| gptkbp:bfsParent |
gptkb:SGI-110
|
| gptkbp:bfsLayer |
7
|